Clarithromycin
Gastric Diffuse Large B-cell Lymphoma
National Health Research Institutes, TaiwanSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Gastric Diffuse Large B-cell Lymphoma cohort.
Same molecule, other indications
Clarithromycin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →